聚苯乙烯磺酸钠与环硅酸锆钠治疗急诊高钾血症的比较
该回顾性队列研究在单中心急诊科纳入2019年8月26日至2021年5月13日期间按「急诊高钾血症治疗」医嘱集接受聚苯乙烯磺酸钠(SPS)或环硅酸锆钠(SZC)的患者,最终分析SPS组54例、SZC组51例。主要终点为给药后血钾从基线至首次复查的变化,两组平均降幅均为-1.1 mEq/L。作者结论为两药降低血钾的效果相似。
要点
- 急诊高钾血症患者使用SPS或SZC后,血钾从基线至首次复查的平均降幅均为-1.1 mEq/L,两组相似。
- 研究为单中心回顾性队列,SPS组54例、SZC组51例,共筛查885例。
- 既往无研究对SPS与SZC进行头对头比较,本研究为此提供了初步数据。
- 阳离子交换树脂的使用基于医生偏好,缺乏高质量数据支持。
适用人群与场景
- 2019年8月26日至2021年5月13日期间在单中心急诊科按「急诊高钾血症治疗」医嘱集接受SPS或SZC治疗的患者。
研究设计与关键结果
- 研究类型:经机构审查委员会批准的回顾性队列研究,单中心急诊科。
- 样本量:共筛查885例,最终纳入SPS组54例、SZC组51例。
- 主要终点:给药后血钾从基线至首次复查的平均变化,SPS组为-1.1 mEq/L,SZC组为-1.1 mEq/L。
- 结论:急诊使用SPS或SZC治疗高钾血症导致相似的血钾降低。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论为急诊使用SPS或SZC治疗高钾血症导致相似的血钾降低,原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Hyperkalemia accounts for over 800,000 emergency department (ED) visits in the United States each year, and has been associated with significant morbidity and mortality likely due to fatal cardiac dysrhythmias. Previous studies have demonstrated reductions in mortality when potassium levels are normalized in the ED. Cation exchange resins, such as sodium polystyrene sulfonate (SPS) and sodium zirconium cyclosilicate (SZC), may be administered as a means of definitively eliminating potassium from the body. This practice is based on physician preference and is not supported by high quality data. Two studies evaluating the use of cation exchange resins versus standard treatment in the ED demonstrated reductions in serum potassium levels within two hours of administration; however, there have been no published studies investigating these agents in a head-to-head comparison.
OBJECTIVE: The purpose of this study was to evaluate the efficacy and safety of SPS versus SZC in lowering serum potassium in patients presenting to the ED with hyperkalemia.
METHODS: This was an institutional review board-approved, retrospective cohort study conducted at a single-site ED. All patients who received medications under the "ED Hyperkalemia Treatment" order set between August 26, 2019 and May 13, 2021 were eligible for inclusion. The primary outcome was the change in serum potassium from baseline to first repeat level following SPS or SZC administration in the ED.
RESULTS: A total of 885 patients were screened with 54 patients in the SPS group and 51 patients in the SZC group included in the final analyses. The mean change in serum potassium from baseline to first repeat level following administration of the cation exchange resin was -1.1 mEq/L for both groups.
CONCLUSION: Administration of SPS or SZC for the treatment of hyperkalemia in the ED resulted in similar reductions in serum potassium.
参考来源
- Hasara S, Dubey J, Amatea J, et al. Sodium polystyrene sulfonate versus sodium zirconium cyclosilicate for the treatment of hyperkalemia in the emergency department. Am J Emerg Med. 2022. PMID: 36586223. doi:10.1016/j.ajem.2022.12.043
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。